Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.5500
Bid (Size) 0.5495 (70)
Ask (Size) 0.5500 (172)
Prev. Close 0.5500
Today's Range 0.5500 - 0.5500
52wk Range 0.2202 - 1.970
Shares Outstanding 55,185,622
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates OMIC, MRNS, VCSA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

YTD
+3.0%
+3.0%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+64.3%
+64.3%
1 Year
-59.3%
-59.3%

More News

Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MoneyLion Inc. (NYSE - ML), Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS), Better Choice Inc. (NYSE American - BTTR), NeueHealth, Inc. (NYSE - NEUE)
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%
Via Benzinga
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Down 1%; Dow Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
Via Benzinga
Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results
Via Benzinga
Dow Falls 150 Points; Tesla Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
From Marinus Pharmaceuticals
Via Business Wire
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Via MarketBeat
Topics ETFs
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Via MarketBeat
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire

Frequently Asked Questions

Is Marinus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Marinus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Marinus Pharmaceuticals, Inc. - Common Stock trade on?
Marinus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Marinus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Marinus Pharmaceuticals, Inc. - Common Stock is MRNS on the Nasdaq Stock Market
What is the current price of Marinus Pharmaceuticals, Inc. - Common Stock?
The current price of Marinus Pharmaceuticals, Inc. - Common Stock is 0.5500
When was Marinus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Marinus Pharmaceuticals, Inc. - Common Stock was at 02/10/25 04:00 PM ET
What is the market capitalization of Marinus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Marinus Pharmaceuticals, Inc. - Common Stock is 30.35M
How many shares of Marinus Pharmaceuticals, Inc. - Common Stock are outstanding?
Marinus Pharmaceuticals, Inc. - Common Stock has 30M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.